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Brazilian 2011GDP per capita), VO was the only cost-effective option compared to 
AB, additionally presenting lower mortality and less hospitalization days while 
allowing early de-hospitalization at private health care services.  
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You J 
The Chinese University of Hong Kong, Shatin, N.T., Hong Kong  
OBJECTIVES: Influenza results in excess morbidity and mortality and therefore 
causes significant burden in a society. Outcomes of the influenza vaccination 
program are influenced by patient acceptance to receive the vaccine. The cost-
effectiveness of influenza vaccine at preventing hospitalization for lower 
respiratory infections in Hong Kong was examined at different levels of 
vaccination coverage. METHODS: A decision model was designed to simulate the 
outcomes of influenza vaccination programs at four different levels of 
vaccination coverage in a hypothetical cohort of elderly aged 65-year-old or 
above who have with no contraindications for influenza vaccine: 1) 16% (current 
vaccination coverage rate in Hong Kong); 2) 35% (vaccination coverage rate in 
some Asian countries; 3) 65%; and 4) 100%. The time horizon was one year. 
Model inputs were derived from literature, and outcome measures were direct 
medical cost (including vaccination) from the health care provider’s perspective, 
influenza-associated mortality rate, and quality-adjusted life-year (QALY) 
gained. Robustness of model results was examined by sensitivity analysis. 
RESULTS: In the base-case scenario, 100% vaccination coverage was associated 
with the lowest cost (USD6.92), the lowest influenza-associated mortality rate 
(0.30 deaths per 10,000 persons) and the highest QALYs gained (0.8358), followed 
by 65% coverage rate (USD8.08; 0.35 deaths per 10,000 persons; 0.8351 QALYs), 
35% coverage rate (USD9.07; 0.39 deaths per 10,000 persons; 0.8345 QALYs) and 
16% rate (USD9.70; 0.42 deaths per 10,000 persons; 0.8342 QALYs). The results 
were robust to variation of all model inputs in sensitivity analysis. 
CONCLUSIONS: In the present model, high coverage rate of influenza 
vaccination seems to be associated with lower direct medical cost, lower 
influenza-associated deaths and higher QALYs.  
 
PIN69  
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OBJECTIVES: HEPLISAV is an investigational hepatitis B virus (HBV) vaccine with 
an adjuvant that specifically targets toll-like receptor 9 and in clinical studies 
provided more rapid and higher rates of seroprotection with fewer doses 
compared with currently available vaccines. We modeled the cost-effectiveness 
of vaccination with HEPLISAV compared with Engerix-B in the prevention of HBV 
infection in select adult populations. METHODS: A Markov model was developed 
for each population of interest: diabetics, patients with chronic or end stage 
kidney disease, health care workers and international travelers to countries with 
high HBV infection prevalence. Disease progression was modeled using 11 health 
states: seroprotected, susceptible, acute infection, chronic infection, fulminant 
hepatic failure, compensated cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma, liver transplant, post-transplant care, and death. Seroprotection rates 
were based on results from two phase 3 clinical trials comparing HEPLISAV with 
Engerix-B and ranged across the various populations from 89-96% for HEPLISAV 
and 62-81% for Engerix-B. Higher vaccination completion rates were assumed for 
HEPLISAV compared with Engerix-B given that fewer doses of HEPLISAV are 
required in a shorter period of time to achieve seroprotection for the evaluated 
populations. Each cycle length represented a 1-year time frame. All future costs 
and benefits were discounted at 3%. A lifetime analysis and a U.S. payer 
perspective were used in this study. RESULTS: HEPLISAV has a favorable cost-
effectiveness profile with incremental cost-effectiveness ratios <$20,000 across 
all populations studied. In the patients with chronic or end stage kidney disease, 
HEPLISAV was the dominant option and was cost-saving compared with Engerix-
B. The cost of vaccine, regimen completion rates, and seroprotection rates were 
the sensitive variables in the models. CONCLUSIONS: HEPLISAV may be a cost-
effective option for HBV vaccination to provide high rates of seroprotection and 
early seroprotection across a range of populations from health care workers to 
patients with chronic or end stage kidney disease.  
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BACKGROUND: For first-line HIV treatment, US treatment guidelines state that 
efavirenz (EFV) is the only preferred non-nucleoside reverse transcriptase 
inhibitor (NNRTI) while nevirapine (NVP) is listed as an acceptable NNRTI. 
Generic versions of NVP were first approved in the US in May 2012. OBJECTIVES: 
To assess the cost-effectiveness of EFV compared with generic NVP in first-line 
HIV treatment in the US. METHODS: A micro-simulation state transition model 
was constructed to estimate the costs (2012 US$) and clinical outcomes for 
antiretroviral naïve HIV patients initiating EFV or NVP. Efficacy and safety data 
was based on the HIV Causal Collaboration Study and a Cochrane Review. 
Published sources were used to identify other inputs. Costs included 
antiretroviral drug acquisition, disease management (based on CD4 counts) and 
adverse events. Health utility was based on CD4 counts and adverse events. A 3% 
discount rate was used for costs and quality-adjusted life years (QALYs). Results 
are based on 100,000 micro-simulation trials with a ten year time horizon. 
RESULTS: Over a 10-year period, EFV was dominant over NVP in the base case 
with lower total costs ($346,932 vs. $364,475), modestly higher QALYs (6.795 vs. 
6.782), and similar life expectancy (9.346 vs. 9.342 years). Keeping all other inputs 
constant, EFV was dominant over generic NVP until the price of NVP was 
reduced to 50% of its base case value. Giving EFV and NVP equal probability of 
treatment success but maintaining basecase adverse event rates and costs 
resulted in an incremental cost effectiveness ratio of $4,438 for EFV compared to 
NVP. CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be cost-
saving compared to generic NVP with modestly higher QALYs and similar life 
expectancy in HIV patients initiating first-line treatment in the US. Sensitivity 
analysis indicated results were not sensitive to NVP price changes.  
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OBJECTIVES: Skin and soft tissue infections caused by Staphylococcus aureus and 
Streptococcus pyogenes are a growing concern in Latin America due to the 
development of more complex resistance profiles to standard antibiotics. The 
aim of this analysis is to estimate the cost-effectiveness of Linezolid in the 
treatment of complicated skin and soft tissue infections (cSSTI) in Colombia. 
METHODS: A decision tree was built to estimate the incremental cost-
effectiveness ratio of the Linezolid (600 IV/twice day) switch (600 orally/twice 
day) compared to Vancomycin (1 g IV/twice day), Daptomycin (4 mg IV/kg/day) 
and Tigecycline (100 mg IV followed by 50 mg twice day). The perspective was 
third payer including direct medical costs only. Effectiveness, safety and utility 
data were extracted from published literature. Unit costs were taken from health 
care institutions. Resource use and costs (drug acquisition, inpatient stay, health 
care professional visits, and lab tests) were considered for the model and 
expressed in 2012 US$. Time horizon was 28 days and effectiveness measures 
were quality-adjusted life-year (QALY’s) and percentage of patients cured. 
RESULTS: Total expected costs for each alternative were: Linezolid US$8,221.7, 
Vancomycin US$10,236.96; Daptomycin US$11,359.69 and Tigecycline 
US$11,255.92. Patients treated with Linezolid were associated with a shorter 
length of stay in the intensive care unit (7 days on average) which reduces 
overall treatment costs due it allows cSSTI patients switching from intravenous 
to oral administration (5 days reduction on average). Results for each alternative 
in terms of QALYs were: Linezolid 0.063, Vancomycin 0.060, Daptomycin 0.061 
and Tigecycline 0.059. Results for each alternative in terms of percentage of 
patients cured were: Linezolid 84.4%; Vancomycin 74.7%; Daptomycin 78.1% and 
Tigecycline 70.4%. The model results indicate that Linezolid would be a 
dominant treatment compared to Vancomycin, Daptomycin and Tigecycline. 
CONCLUSIONS: Linezolid seems to be a cost-saving option for the treatment of 
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OBJECTIVES: For first-line treatment of HIV, US treatment guidelines 
recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir 
(EFV/FTC/TDF) as a preferred regimen and the once-daily tablet of 
elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/cobi/FTC/TDF) as an 
alternative regimen. This study assessed the clinical and economic trade-offs 
involved in using EVG/cobi/FTC/TDF compared with EFV/FTC/TDF in first-line 
HIV antiretroviral therapy (ART) in US adults. METHODS: A Markov cohort model 
was developed to project lifetime health-related outcomes, costs, quality-
adjusted life years (QALYs), and cost-effectiveness of EVG/cobi/FTC/TDF 
compared with EFV/FTC/TDF as first-line ART in the US. HIV patients progressed 
in 12-week cycles through second-line, third-line, and non-suppressive 
therapies, AIDS, and death. Baseline characteristics and first-line virologic 
suppression, change in CD4 count, and adverse effects (lipid, central nervous 
system, rash, and/or renal) were based on 48-week clinical trial results. These 
results demonstrated equivalent virologic suppression between the two 
regimens. Point estimates for virologic suppression (favoring EVG/cobi/FTC/TDF) 
were used in the base case, and equivalency in scenario analysis. Published 
sources and expert opinion were used to estimate costs, utilities, AIDS risk, 
mortality, and subsequent-line CD4 count, efficacy and adverse events. Costs 
were reported in 2012 US dollars. Sensitivity analyses were conducted to assess 
robustness of results. RESULTS: Compared with patients initiating EFV/FTC/TDF, 
patients initiating EVG/cobi/FTC/TDF were estimated to have higher lifetime 
costs. EVG/cobi/FTC/TDF added 0.087 QALYs over a lifetime at a cost of $10,843, 
producing an incremental cost-effectiveness ratio of $124,101/QALY gained. 
Results were most sensitive to first-line response, product costs, and likelihood 
of renal adverse events. When equivalent efficacy was assumed, EFV/FTC/TDF 
dominated EVG/cobi/FTC/TDF with lower costs (-$12,305) and greater QALYs 
(0.047). CONCLUSIONS: At a societal willingness to pay of $100,000/QALY, 
EVG/cobi/FTC/TDF was not cost effective in the base case compared with 
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EFV/FTC/TDF for first-line HIV treatment. In scenario analysis assuming 
equivalent efficacy, EFV/FTC/TDF dominated EVG/cobi/FTC/TDF with lower costs 
and greater QALYs.  
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OBJECTIVES: The objective of this research is to evaluate the cost-effectiveness 
of linezolid 600mgBID(LI), vancomycin 1gBID(VA) and teicoplanin 400mgBID(TE) 
in the treatment of nosocomial pneumonia caused by MRSA under the public 
health care system perspective. METHODS: To compare the options, a decision 
tree model was built considering an arm per treatment option, from which 
patients could respond to the initial treatment and continue to a maintenance 
treatment using the same antibiotics, or do not respond, and repeat the 
treatment with assumed 50% chance to use one of the other two antibiotics. 
Clinical or microbiological effectiveness could be used as determinants of 
response. Effectiveness measures were mortality, clinical and microbiological 
responses, calculated by an indirect comparison of a literature systematic 
review. Hospitalization days were evaluated. Only direct costs were considered, 
and were obtained from DATASUS/SIGTAP 2012 for medical procedures,  
and DATASUS/BPS considering the average of purchases from November 2011 to 
October 2012 for medications and materials, as the latest data available. Values 
were represented in 2012USD. A time horizon of 1 year was considered. 
RESULTS: Clinical response rates were 66.5%(VA), 68.3%(TE), 72.6%(LI), 
microbiological response rates were 56.1%(VA), 55.9%(TE), 64.4%(LI), mortality 
rates were 15.74%(VA), 13.56%(TE), 10.13%(LI). If clinical response was considered 
as a determinant of success, the treatment costs would be 13,806.58USD(VA), 
14,279.01USD(TE), 15,301.44USD(LI), hospitalization days would be 41(VA),  
39(TE), 26(LI), and if microbiological response was considered, the treatment 
costs would be 14,637.39USD(VA); 15,169.33USD(TE), 15,793.21USD(LI) and 
hospitalization days would be 42(VA), 40(TE), 28(LI). Incremental cost-
effectiveness ratios for TE and LI when compared to VA for clinical response 
were 26,246.03USD, 24,505.90USD, and for microbiological response were  
-26,597.03USD(dominated), 13,925.46USD respectively. CONCLUSIONS: Assuming 
a willingness to pay of 32,621.93USD (3 times Brazilian 2011GDP per capita), 
linezolid was the most cost-effective option compared to vancomycin, 
additionally presenting lower mortality and less hospitalization days at public 
health care services.  
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OBJECTIVES: Clinically, interferon-alpha (IFN-α) is used for inhibiting hepatitis B 
and C virus infection, but IFN-α treatment may cause side effects of depression. 
Recent study has reported that serum serotonin levels are associated with 
antiviral therapy outcomes in patients with chronic hepatitis C. The aim of this 
study was to evaluate the cost and effectiveness of antidepressants in hepatitis C 
patients treated with interferon. METHODS: This is a retrospective study from 
January 1, 2002 to December 31, 2010 using Chi-Mei Medical Center claim data. 
Subjects were divided into exposure and control groups. The exposure group 
included patients treated with IFN-α or combined antiviral drugs and 
antidepressants for at least 6 months. The control group was those without 
antidepressant treatment. The endpoints were evaluated liver related lab data, 
the number of visits to the out-patient department, emergency department or 
admission during treatment, and the cost. RESULTS: There were a total of 135 
patient diagnosed hepatitis B or C and treated with IFN-α or combined antiviral 
drugs. Comparing the exposure and control groups, the control group had a 
higher SGOT (53.97±40.0 vs. 93.16±64.54 IU/L, 95% CI=28.12~50.3, P<0.05); SGPT 
(62.07±5. IU/L vs. 316.36±123.4 IU/L, 95% CI=79.95~122.64, P<0.05), AFP (9.8±22.4 
ng/mL vs. 11.79±18.1 ng/mL, 95% CI=-1.77~5.7, P=0.304). Comparing mean health 
care costs in six months is NT 263,200 for exposure group and 242,600 for control 
group. No significant difference. That may be related to psychiatric visits and 
medication use. CONCLUSIONS: These results suggest that antidepressants may 
play an important role in hepatitis B or C patients treated with IFN-α or 
combined antiviral drugs. Future studies are needed to further clarify the 
mechanisms of antidepressant action.  
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OBJECTIVES: A pneumococcal 7-valent conjugate vaccine (PCV7) was launched 
as a Category II vaccine requiring out-of-pocket payment in China in 2008. The 
objective of this study was to estimate the expected health benefits, cost, and 
incremental cost-effectiveness of introducing a public financed City 
Immunization Program (CIP) to pay for PCV7 from a social perspective in the long 
term. METHODS: A Markov cohort model was used to estimate cost and 
epidemiological burden of invasive pneumococcal disease (IPD), pneumonia and 
otitis media for all age cohort in Beijing, Guangzhou, Shenzhen and Wuhan 
within five years. Data includes cost data from eight hospitals in four cities as 
well as epidemiological data from Bureau of National Health Insurance in 
Taiwan. Outcomes were measured by reduction in disease burden, cost, quality-
adjusted life years (QALYs) and incremental cost-effectiveness ratio. In addition 
we performed sensitivity analyses for key parameters. RESULTS: Due to this 
immunization program, 11793 people may avoid dying, 42265.49 QALYs were 
generated additionally in the four cities within five years. Besides, this program 
may reduce the disease burden about RMB 1,574.7 per person. CONCLUSIONS: 
Integrating PCV7 into CIP has remarkable cost-effectiveness. It would possibly 
bring more net benefit with the increasing rate of immunization.  
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OBJECTIVES: Streptococcus pneumoniae is an important gram-positive pathogen 
with more than 90 serotypes, responsible for invasive pneumococcal diseases 
(IPD) (meningitis, bacteremia) and noninvasive diseases (pneumonia, otitis acute 
middle [OAM]). This analysis is aimed to estimate the cost-effectiveness of 
pneumococcal conjugate vaccines PCV13 and PCV10 in terms of prevention of 
diseases and deaths by IPD, radiologically confirmed pneumonia, AOM, and life 
years gained (LYG) in a cohort of newborns in Colombia. METHODS: A decision 
tree was developed with national data including the distribution of 
pneumococcal serotypes in Colombia between 2009 and 2011. Comparators were: 
PCV13, PCV10 (scheme 2 + 1) against no vaccination; vaccine coverage of 90 % 
was assumed (699,975 children). The simulation of newborns in Colombia took 
place within a time horizon of 5 years and a discount rate of 3%. The analysis 
used the third-party payer perspective. The efficacy values of the vaccines were 
determined by a systematic review. Medical costs are expressed in 2012 US$ and 
were provided by “SURA” a Colombian health insurance company. Probabilistic 
sensitivity analyses for epidemiological, efficacy and cost parameters were 
performed. RESULTS: After 5 years of follow-up, PCV13 would prevent 426 deaths 
due to pneumococcal infections versus 331 that would be prevented by PCV10, 
compared to no vaccination. PCV13 and PCV10 would generate 25,212 LYG and 
19,584 LYG, respectively. Medical costs avoided would be US$19,920,837 and 
US$15,094,775, respectively. Compared to no vaccination, PCV13 and PCV10 were 
cost-effective, with cost-effectiveness ratio of US$570.35 and US$768.57 per LYG; 
although, PCV13 was dominant over PCV10 due to lower total costs and better 
health outcomes. CONCLUSIONS: PCV13 is a cost-saving strategy compared with 
PCV10, as part of a mass vaccination program in Colombian children under one 
year. PCV13 is expected to lead to a greater decrement in infant mortality from 
pneumococcal diseases.  
 
PIN77  
COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINES FOR ADULTS IN THE 
UNITED STATES  
Yang HK1, Chen J2, O'Brien M1, Grabenstein J1, Dasbach E2 
1Merck & Co, Inc., West Point, PA, USA, 2Merck & Co, Inc., North Wales, PA, USA  
OBJECTIVES: In 2012, the U.S. Advisory Committee on Immunization Practices 
(ACIP) revised their 1997 adult pneumococcal vaccination recommendations to 
include a sequential regimen of 13-valent pneumococcal conjugate vaccine 
(PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for 
certain high-risk adults with immunocompromising conditions, while 
continuing routine PPSV23 use for healthy and immunocompetent adults with 
comorbidities. This study aims to examine: 1) cost-effectiveness of the 2012 ACIP 
recommendations relative to 1997 recommendations; 2) cost-effectiveness of 
potential future pneumococcal vaccination policies; 3) key assumptions that 
influence study results. METHODS: A static cohort model that incorporated 
costs, health outcomes, and quality-adjusted life-year (QALY) losses associated 
with invasive pneumococcal disease and non-bacteremic pneumococcal 
pneumonia (NBPP) was developed to evaluate the cost-effectiveness of seven 
pneumococcal vaccination strategies for an adult cohort 50 years of age using 
incremental cost-effectiveness ratios (ICERs). RESULTS: For aim 1, the 2012 ACIP 
recommendation was found to be the most economically efficient strategy (ICER 
of $14,781 per QALY gained). For aim 2, when the set of strategies evaluated was 
broadened to consider potential future policies, the most economically efficient 
strategy was modifying the 2012 recommendation for adults with 
immunocompromising conditions to include a sequential regimen of PCV13 and 
PPSV23 (ICER of $13,775 per QALY gained). For aim 3, cost-effectiveness ratios for 
alternative vaccination strategies were highly influenced by assumptions about 
vaccine effectiveness in NBPP and accounting for herd protection effects of 
pediatric pneumococcal vaccination on adult pneumococcal disease. 
CONCLUSIONS: Extending the 2012 ACIP recommendation to include a 
sequential regimen of PCV13 and PPSV23 at age 65 for adults with 
immunocompromising conditions appears to be a cost-effective vaccination 
policy. Given the uncertainty in available data and absence of key influential 
data related to vaccine effectiveness and herd protection, policy-makers should 
conduct comprehensive sensitivity analyses when evaluating new 
pneumococcal vaccine strategies in adults.  
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OBJECTIVES: Guidelines for management of genotype 1 chronic hepatitis C (CH-
C) patients recommend a liver biopsy and treating patients with significant 
